| Original language | English |
|---|---|
| Journal | Journal of Medical Ethics |
| Early online date | 16 Feb 2023 |
| DOIs | |
| Publication status | Published - 9 Mar 2023 |
Access to Document
- Cost effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first line treatment of postmenopausal women with
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Accepted author manuscript, 1.32 MB - Cost effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first line treatment of postmenopausal women with
ß 2023 Novartis. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. www.tandfonline.com/ijme
Final published version, 1.75 MB
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Medical Ethics, 09.03.2023.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
AU - Cameron, David A
AU - Kumar Sharma, Vikash
AU - Biswas, Chandroday
AU - Clarke, Cathy
AU - Chandiwanna, David
AU - Pathak, Purnima
N1 - Funding Information: DCa: research funding from Exact Sciences, Novartis and Sanofi; consultant for Lilly, Novartis and Pfizer; VKS: employee of Novartis Healthcare Pvt Ltd, Hyderabad, India; CB: employee of Novartis Healthcare Pvt Ltd, Hyderabad, India; CC: employee of Novartis Pharmaceuticals UK Ltd, London, UK; DCh: employee of Novartis Services Inc., East Hanover, NJ, USA; PP: employee of Novartis Services Inc., East Hanover, NJ, USA. Funding Information: This study was sponsored by Novartis Pharmaceuticals. Support for third-party writing assistance for this article, provided by Patrick Cox, BSc, and Fern Woodhouse, MChem, from Costello Medical, UK, was funded by Novartis Pharmaceuticals in accordance with Good Publication Practice (GPP 2022) guidelines ( GPP 2022 [ismpp.org] ). Funding Information: The authors acknowledge Patrick Cox and Fern Woodhouse, from Costello Medical, UK, for medical writing and editorial assistance based on the authors’ input and direction. Publisher Copyright: © 2023 Novartis. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023/3/9
Y1 - 2023/3/9
U2 - 10.1080/13696998.2023.218205
DO - 10.1080/13696998.2023.218205
M3 - Article
SN - 0306-6800
JO - Journal of Medical Ethics
JF - Journal of Medical Ethics
ER -